Patient no.	Age (Years)	Sex	Treatment	Best RECIST response	Progression Free Survival (Days)	Overall Survival (Days)	Site of PRE Biopsy	Days to EDT Biopsy	Site of EDT Biopsy	Progressed	Last Followup Status	RNA Sequencing	Immunofluorescence Panel 1	Immunofluorescence Panel 2
1	48	F	Nivolumab	PD 	9	147	LN	7	SQ	Yes	Dead, melanoma	-	PRE 	PRE and EDT
2	61	F	Pembrolizumab	PD	13	65	SQ	-	-	Yes	Dead, melanoma	PRE	-	-
3	50	M	Nivolumab	PD	23	59	SQ	15	SQ	Yes	Dead, melanoma	PRE	EDT	EDT
4	84	M	Pembrolizumab	PD 	23	22	SQ	9	SQ	Yes	Dead, melanoma	PRE	PRE and EDT	PRE and EDT
5	67	M	Pembrolizumab	PD	39	155	SQ	-	-	Yes	Dead, melanoma	PRE	PRE	PRE
6	68	M	Nivolumab	PD	42	94	LN	-	-	Yes	Dead, melanoma	PRE	PRE	PRE
7	57	F	Nivolumab	PD	47	80	LN	19	SQ	Yes	Dead, melanoma	PRE	PRE and EDT	EDT
8	85	F	Nivolumab	PD 	58	58	SQ	6	SQ	Yes	Dead, melanoma	PRE and EDT	PRE and EDT	PRE
9	70	F	Pembrolizumab	PD 	71	99	SQ	-	-	Yes	Dead, melanoma	PRE	-	-
10	90	M	Pembrolizumab	PD 	76	551	SQ	7	SQ	Yes	Alive	PRE and EDT	PRE	PRE
11	66	M	Pembrolizumab	PD	78	166	SQ	-	-	Yes	Dead, melanoma	PRE	-	-
12	52	M	Pembrolizumab	SD	80	199	SQ	14	SQ	Yes	Dead, melanoma	PRE	PRE and EDT	PRE and EDT
13	69	M	Pembrolizumab	PD	82	96	SQ	6	SQ	Yes	Dead, melanoma	PRE and EDT	PRE and EDT	PRE and EDT
14	58	M	Pembrolizumab	PD	83	993	Mucosa	-	-	Yes	Dead, melanoma	PRE	PRE	PRE
15	76	F	Pembrolizumab	PD	84	300	SQ	-	-	Yes	Dead	PRE	-	-
16	55	M	Pembrolizumab	PD	84	169	LN	-	-	Yes	Dead, melanoma	PRE	-	-
17	37	M	Pembrolizumab	PD	96	258	SQ	9	Spine	Yes	Dead, melanoma	PRE and EDT	PRE and EDT	PRE
18	62	M	Pembrolizumab	PD	100	228	SQ	-	-	Yes	Dead, melanoma	PRE	PRE	PRE
19	54	M	Pembrolizumab	SD	125	385	SQ	-	-	Yes	Dead, melanoma	PRE	PRE	PRE
20	45	F	Pembrolizumab	PR	156	553	Brain	-	-	Yes	Dead, melanoma	-	PRE	PRE
21	67	M	Pembrolizumab	SD	166	551	SQ	-	-	Yes	Dead, melanoma	PRE	PRE	PRE
22	69	F	Pembrolizumab	SD	176	379	SQ	-	-	Yes	Alive	-	PRE	PRE
23	40	M	Nivolumab	SD	191	191	SQ	10	SQ	Yes	Dead, melanoma	PRE	PRE and EDT	PRE and EDT
24	54	F	Pembrolizumab	SD	197	407	SQ	28	SQ	Yes	Dead, melanoma	-	PRE and EDT	PRE and EDT
25	49	M	Nivolumab	PR	271	897	SQ	43	SQ	Yes	Dead, melanoma	PRE and EDT	PRE and EDT	PRE and EDT
26	89	F	Pembrolizumab	CR 	275	275	SQ	10	SQ	No	Alive	-	PRE and EDT	PRE and EDT
27	76	M	Pembrolizumab	PR	314	1067	SQ	-	-	Yes	Dead, melanoma	PRE	-	-
28	81	M	Pembrolizumab	PR	324	324	SQ	44	SQ	No	Alive	-	PRE and EDT	PRE and EDT
29	55	M	Pembrolizumab	SD	335	825	SQ	68	SQ	Yes	Dead, melanoma	PRE and EDT	-	-
30	86	F	Pembrolizumab	SD 	358	581	SQ	-	-	Yes	Alive	PRE	PRE	PRE
31	74	F	Nivolumab	PR	365	365	SQ	-	-	No	Alive	-	PRE	PRE
32	69	F	Pembrolizumab	CR 	460	460	Brain	14	SQ	No	Alive	-	PRE	EDT
33	76	M	Pembrolizumab	CR 	477	477	LN	-	-	No	Alive	-	PRE	PRE
34	78	M	Pembrolizumab	PR	544	878	LN	-	-	Yes	Dead, melanoma	PRE	PRE	PRE
35	55	F	Pembrolizumab	PR	586	1091	SQ	-	-	Yes	Alive	PRE	-	-
36	76	M	Nivolumab	PR	590	607	SQ	-	-	Yes	Dead, melanoma	PRE	PRE	PRE
37	66	M	Pembrolizumab	CR	647	910	SQ	7	SQ	Yes	Alive	-	PRE and EDT	PRE and EDT
38	69	F	Pembrolizumab	PR	755	1547	SQ	-	-	Yes	Alive	PRE	-	-
39	72	M	Pembrolizumab	SD	815	815	SQ	-	-	No	Alive	-	PRE	PRE
40	78	M	Pembrolizumab	PR	845	845	SQ	-	-	No	Alive	PRE	PRE	PRE
41	61	F	Pembrolizumab	PR	870	886	SQ	10	SQ	Yes	Alive	PRE and EDT	PRE and EDT	PRE and EDT
42	59	F	Pembrolizumab	CR	891	891	SQ	-	-	No	Alive	PRE	-	-
43	63	M	Pembrolizumab	CR	905	905	SQ	-	-	No	Alive	-	PRE	PRE
44	45	F	Pembrolizumab	PR	1075	1075	LN	-	-	No	Alive	PRE	-	-
45	82	M	Pembrolizumab	PR	1085	1085	SQ	-	-	No	Alive	PRE	-	-
46	71	M	Pembrolizumab	PR	1098	1098	SQ	-	-	No	Alive	PRE	PRE	PRE
47	62	M	Pembrolizumab	PR	1174	1174	SQ	7	SQ	No	Alive	PRE and EDT	-	-
48	40	M	Pembrolizumab	PR	1189	1189	SQ	3	LN	No	Alive	PRE and EDT	-	-
49	72	F	Nivolumab	CR	1328	1328	SQ	2	SQ	No	Alive	PRE	PRE and EDT	PRE and EDT
50	86	M	Nivolumab	CR	1342	1342	SQ	-	-	No	Alive	PRE	PRE	PRE
51	64	M	Nivolumab	CR	1397	1397	SQ	-	-	No	Alive	-	PRE	PRE
52	63	F	Pembrolizumab	PR	1553	1553	SQ	-	-	No	Alive	PRE	PRE	PRE
53	71	F	Pembrolizumab	CR	1589	1589	LN	-	-	No	Alive	PRE	-	-
54	52	F	Pembrolizumab	PR	1603	1603	SQ	-	-	No	Alive	PRE	PRE	PRE
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														
														